Skip to main content

Table 2 Table summarising treatments used

From: Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management

   Systemic treatments Systemic CS Topical treatments
MTX MMF TCZ ADA AZA ETN ANK CiC IV PO CS Vit D Tac
Current treatment No of patients 63 30 8 3 1 0 1 0 8 3 4 3 4
Median duration treatment months (IQR) 16.0 (9.3–24) 13.0 (6.0–25.5) 17.5 (15.8–24.0) 26.3 14 n/a 31 n/a 7.0 (3.5–10) 9.3    
Previous treatment No of patients 79 17 0 0 0 4 0 2 106 49 48 14 22
Remissiona 34 5 n/a n/a n/a 0 n/a 0 103a 45a    
Inefficacy 8 6 n/a n/a n/a 3 n/a 2 0 3    
Intolerance 37 6 n/a n/a n/a 1 n/a 0 3 1    
Never given No of patients 7 102 141 146 148 145 148 147 35 97 97 132 123
  1. MTX Methotrexate, MMF Mycophenolate mofetil, TCZ Tocilizumab, ADA Adalimumab, AZA Azathioprine, ETN Etanercept, ANK Anakinra, CiC Ciclosporin, IV Intravenous, PO Oral, CS Corticosteroid, Vit D Vitamin D analogue, Tac Tacrolimus, IQR Interquartile range
  2. aPatients treated with steroids were often given a standard treatment course whilst being established on a DMARD/biologic which is stopped after a standard interval according to local protocol rather than remission
  3. The indication for commencement of a biological was not captured in this audit. A biological may have been commenced for refractory skin involvement or extra-cutaneous manifestations such as uveitis, CNS involvement or synovitis